Two high-dose radiation treatments for early prostate cancer
Part of Cancer clinical trials.
This trial tests a shorter course of high-dose radiation therapy for prostate cancer that hasn't spread. It aims to make treatment more convenient while keeping it effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with prostate cancer that is considered intermediate-risk and hasn't spread.
- You are 18 years or older.
- You are generally healthy and able to undergo anesthesia.
- You have not had any prior treatment for prostate cancer.
- Your prostate is not too large (less than 60 cubic centimeters).
- Your urinary symptoms are not severe (IPSS score less than 15).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining standard hormone therapy and radiation with a special targeted radiation (PSMA-targeted radiotherapy) is safe and effective for men with high-risk prostate cancer that hasn't spread outside the pelvis.
This trial tests whether a shorter course of radiation works as well as the usual longer course for people with high-risk prostate cancer. The goal is to keep cancer control while possibly reducing treatment time and inconvenience.
This trial studies a combination of two radiation types—high-dose-rate brachytherapy and stereotactic body radiotherapy—to treat certain intermediate- to high-risk prostate cancers. It may help by aiming radiation closely at the prostate while also targeting the cancer from outside the body.
This trial tests whether giving a short course of hormone therapy (apalutamide) along with targeted, high-dose radiation (SBRT) is safe and effective for men with a specific type of intermediate-risk prostate cancer. You may benefit if you fit the exact risk and test criteria.
This trial studies how safe and effective different high-dose radiation levels are for prostate cancer placed directly in the prostate (HDR brachytherapy). It may help by finding a dose that controls the cancer while keeping side effects acceptable.
This trial tests whether a single, high dose of radiation can treat low- to intermediate-risk prostate cancer. It may be a shorter and more convenient option for eligible patients.
Hear when a new Prostate Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.